IVA — Inventiva S.A. Stock Price, Chart & AI Report

Positive Jun 16, 2026 • 08:52 UTC GlobeNewswire Inc. • Claret Capital Partners

Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development

Claret Capital Partners has invested €43m in clinical-stage biopharmaceutical company Inventiva as part of a €130m debt financing round. Inventiva is developing lanifibranor, an oral therapy for MASH (metabolic dysfunction-associated steatohepatitis), with Phase 3 trial results expected in Q4 2026. The financing, alongside BlackRock-managed funds, aims to support the company through key clinical and regulatory milestones.

IVA BLK DIVB growth debt financing biopharmaceutical MASH treatment lanifibranor Phase 3 clinical trial

Sentiment note

Company secured substantial €130m financing commitment with participation from reputable investors (Claret Capital and BlackRock), demonstrating confidence in its clinical program. Phase 3 trial readout expected in Q4 2026 represents a significant near-term catalyst. Strong management commentary indicates financial and operational readiness for critical milestones.

Positive Jun 12, 2026 • 20:00 UTC GlobeNewswire Inc. • Na

Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing

Inventiva completed repayment of €62 million in EIB loans and repurchased EIB warrants for €50 million. The company simultaneously issued €75 million in new debt financing (€35 million convertible bonds and €40 million amortized bonds) from BlackRock and Claret Capital Partners, following a successful €120 million equity offering of ADSs at $4.40 per share.

IVA BLK DIVB debt refinancing convertible bonds warrant repurchase equity offering MASH treatment

Sentiment note

The company successfully executed a major refinancing transaction, replacing expensive EIB debt with more favorable terms from institutional investors (BlackRock and Claret Capital Partners). The completion of a €120 million equity offering and €75 million debt financing demonstrates strong investor confidence and provides substantial capital runway for clinical development of its MASH treatment candidate.

Neutral Jun 9, 2026 • 20:00 UTC GlobeNewswire Inc. • Inventiva

Combined General Meeting of June 30, 2026 - Availability of the Preparatory Documents

Inventiva, a clinical-stage biopharmaceutical company developing oral therapies for MASH, announced the availability of preparatory documents for its Combined General Meeting scheduled for June 30, 2026. The meeting agenda includes a 39th resolution related to a master agreement with the European Investment Bank (EIB) for full repayment of existing loans and buyback of warrants for €50 million, with issuance of new warrants on standard terms. The company is currently evaluating lanifibranor in the NATiV3 Phase 3 clinical trial.

IVA MASH treatment lanifibranor pan-PPAR agonist Phase 3 clinical trial European Investment Bank warrant buyback shareholder meeting

Sentiment note

The announcement is procedural in nature, detailing shareholder meeting logistics and a debt restructuring agreement with the EIB. While the €50 million warrant buyback could be viewed positively as debt management, the extensive forward-looking statements and risk disclosures highlight significant uncertainties regarding clinical trial outcomes, regulatory approval, and the company's ability to continue operations without additional capital, warranting a neutral stance.

Neutral Jun 9, 2026 • 20:00 UTC GlobeNewswire Inc. • Na

Information relative au nombre total de droits de vote et d’actions composant le capital social au 22 mai 2026

Inventiva, a clinical-stage biopharmaceutical company, announced the resumption of trading for its ordinary shares on Euronext Paris and provided information on its Combined General Meeting scheduled for June 30, 2026. As of May 22, 2026, the company had 209,007,475 shares in circulation with 218,082,368 total voting rights.

IVA Inventiva biopharmaceutical MASH treatment lanifibranor pan-PPAR agonist clinical-stage Euronext Paris

Sentiment note

The article reports factual corporate governance information regarding trading resumption and shareholder meeting details. While the company is advancing a Phase 3 clinical trial (NATiV3) for lanifibranor, the article itself contains no clinical results, regulatory updates, or business developments that would warrant positive or negative sentiment. It is purely administrative in nature.

Neutral Jun 9, 2026 • 20:00 UTC GlobeNewswire Inc. • Inventiva

Assemblée Générale Mixte du 30 juin 2026 - Modalités de mise à disposition des documents préparatoires

Inventiva announced the arrangements for its Mixed General Assembly scheduled for June 30, 2026 in Paris. The agenda includes a 39th resolution regarding a master agreement with the European Investment Bank (EIB) signed on June 1, 2026, which involves full repayment of existing EIB loans and repurchase of warrant subscription rights (BSA) for €50 million. The company also adjusted caps for resolutions related to free share allocations and warrant issuances based on recent board decisions.

IVA Mixed General Assembly European Investment Bank loan repayment warrant buyback MASH treatment lanifibranor clinical trial NATiV3

Sentiment note

The announcement is procedural in nature, detailing shareholder meeting arrangements and a debt refinancing agreement with the EIB. While the €50 million warrant buyback and loan repayment could be viewed positively as debt management, the overall tone is administrative and informational without material positive or negative developments regarding the company's clinical pipeline or financial position.

Neutral Jun 9, 2026 • 20:00 UTC GlobeNewswire Inc. • Na

Statement of Total Voting Rights and Shares Forming The Company’s Share Capital as of May 22, 2026

Inventiva, a clinical-stage biopharmaceutical company, announced the resumption of trading for its ordinary shares on Euronext Paris and disclosed preparatory documents for its Combined General Meeting scheduled for June 30, 2026. The company has 209,007,475 shares outstanding with 218,082,368 total voting rights as of May 22, 2026.

IVA Inventiva trading resumption Euronext Paris NASDAQ biopharmaceutical lanifibranor MASH treatment

Sentiment note

The article reports factual corporate governance events (trading resumption and shareholder meeting announcement) without indicating positive or negative developments. No clinical trial results, regulatory decisions, or business performance metrics are disclosed that would warrant a positive or negative sentiment.

Neutral Jun 2, 2026 • 05:30 UTC GlobeNewswire Inc. • Na

Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris

Inventiva, a clinical-stage biopharmaceutical company developing oral therapies for MASH treatment, announced a temporary trading halt on Euronext Paris on June 2, 2026, ahead of a proposed financing transaction. Trading was expected to resume at approximately 3:30 p.m. CEST, coinciding with the opening of Nasdaq trading. The company reported Q1 2026 cash and equivalents of €75.0 million plus €121.5 million in short-term deposits.

IVA trading halt financing transaction MASH treatment lanifibranor NATiV3 Phase 3 trial biopharmaceutical Euronext Paris

Sentiment note

The announcement of a financing transaction is typically positive for a clinical-stage biotech company, indicating investor confidence and funding to advance development. However, the sentiment is tempered to neutral due to lack of specific details about the financing terms, amount, or strategic implications. The company maintains a solid cash position (€196.5 million combined), which is neither alarming nor exceptional for a clinical-stage firm.

Neutral Jun 2, 2026 • 05:30 UTC GlobeNewswire Inc. • Na

Inventiva annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris

Inventiva announced on June 2, 2026, that trading of its ordinary shares on Euronext Paris will be temporarily suspended starting at market open (9:00 CEST) pending disclosure of a financing operation. Trading is expected to resume later that day around 15:30 CEST, coinciding with potential trading resumption on Nasdaq. The company is a clinical-stage biopharmaceutical firm developing lanifibranor, a pan-PPAR agonist, for treating MASH (metabolic dysfunction-associated steatohepatitis).

IVA trading suspension financing operation Euronext Paris Nasdaq lanifibranor MASH treatment clinical-stage biopharmaceutical

Sentiment note

The announcement of a trading suspension ahead of a financing operation is procedurally neutral. While financing typically indicates capital needs, the suspension itself is a standard regulatory procedure. Without details on the financing terms or impact, sentiment remains neutral pending further disclosure.

Neutral May 26, 2026 • 20:00 UTC GlobeNewswire Inc. • Na

Inventiva Reports 2026 First Quarter Financial Information¹

Inventiva, a clinical-stage biopharmaceutical company, reported Q1 2026 financial results showing cash and cash equivalents of €75.0 million and short-term deposits of €121.5 million, down from €99.3 million and €131.6 million respectively at year-end 2025. The company estimates its current resources will fund operations until mid-Q1 2027, or mid-Q3 2027 if Tranche 3 warrants from its October 2024 structured financing are fully exercised for €116.0 million. The company generated no revenues in Q1 2026 and expects NATiV3 Phase 3 trial topline results in Q4 2026.

IVA MASH treatment lanifibranor Phase 3 clinical trial cash runway structured financing NATiV3 trial pan-PPAR agonist

Sentiment note

The company reported declining cash reserves (down €24.3M quarter-over-quarter) with no revenue generation, indicating ongoing cash burn typical for clinical-stage biotech. However, the company maintains adequate runway until at least Q1 2027 and has potential additional funding through warrant exercises. The upcoming NATiV3 Phase 3 trial results in Q4 2026 represent a key catalyst, but the outcome remains uncertain. The neutral sentiment reflects the balanced view of adequate near-term funding against typical clinical-stage risks and lack of revenue.

Neutral May 26, 2026 • 20:00 UTC GlobeNewswire Inc. • Na

Inventiva publie ses informations financières du premier trimestre 2026¹

Inventiva, a clinical-stage biopharmaceutical company, reported cash and equivalents of €75 million and short-term deposits of €121.5 million as of March 31, 2026. The company estimates its liquidity will fund operations until mid-Q1 2027, or potentially mid-Q3 2027 if warrant exercises from its structured financing reach €116 million. No revenue was recorded in Q1 2026. Key milestone: NATiV3 Phase 3 trial results for lanifibranor (MASH treatment) are expected in Q4 2026.

IVA cash position liquidity runway lanifibranor MASH treatment NATiV3 trial clinical-stage biotech warrant financing

Sentiment note

The company maintains adequate liquidity (€196.5M combined cash and deposits) to fund operations into 2027, but faces typical clinical-stage biotech risks. No revenue generation and dependence on trial outcomes and future financing create uncertainty. The Q1 cash burn (€24.3M decrease) is expected but the company's runway depends on warrant exercises and trial success, which are not guaranteed.

Positive May 21, 2026 • 20:00 UTC GlobeNewswire Inc. • Not Specified

Inventiva to Present at 2026 Jefferies Global Healthcare Conference

Inventiva, a clinical-stage biopharmaceutical company developing oral therapies for MASH treatment, announced that CEO Andrew Obenshain will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, in New York City. The company is evaluating lanifibranor, a pan-PPAR agonist, in the NATiV3 Phase 3 clinical trial.

IVA Inventiva biopharmaceutical MASH lanifibranor Phase 3 clinical trial Jefferies Global Healthcare Conference pan-PPAR agonist

Sentiment note

The company is advancing its lead candidate lanifibranor through a pivotal Phase 3 trial (NATiV3) for MASH treatment, strengthening its leadership team ahead of expected data readout, and presenting at a major healthcare conference, all indicating progress toward potential commercialization and investor confidence.

Positive May 21, 2026 • 20:00 UTC GlobeNewswire Inc. • Na

Inventiva présentera lors de la 2026 Jefferies Global Healthcare Conference

Inventiva announced that CEO Andrew Obenshain will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026 in New York. The biopharmaceutical company is developing lanifibranor, an oral therapy for MASH treatment, currently in Phase 3 clinical trials.

IVA Inventiva Jefferies Global Healthcare Conference lanifibranor MASH Phase 3 clinical trial biopharmaceutical oral therapy

Sentiment note

The company is advancing its lead candidate lanifibranor through Phase 3 clinical trials for MASH treatment and is presenting at a major healthcare conference, indicating progress in development and investor engagement. The mention of strengthening the leadership team ahead of expected Phase 3 data readout suggests confidence in upcoming milestones.